Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scancell Holdings plc (SCNLF)
Oxford, GB
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.90% | +6.90% | +90.64% | +60.59% | +139.93% | +124.93% | +90.75% | +47.23% | +29.56% | +28.53% | -28.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-10.6%
-
EPS growth Biotechnology: +29.7%-85.3% Q4'25: -106.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-386.2%
-
EBIT margin Biotechnology: +0.0%-318.4%
-
ROIC Biotechnology: -16.1%— Q4'25: +2,574.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+12.5% Q4'25: +46.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.12× Q4'25: -0.74× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 2 Rev. Ana. 1 EPS Ana. |
Apr 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
5.27M
est: 4.43M (+19.1%)
|
5.27M
est: 2.64M (+100.0%)
|
4.71M
est: 5.67M (-16.9%)
|
1.25M
1.25M – 1.25M
-77.9% YoY
|
1.19M
1.19M – 1.19M
-5.0% YoY
|
| EBITDA |
-12.19M
est: -885.3K (-1,276.6%)
|
-12.19M
est: -527.1K (-2,212.3%)
|
-14.51M
est: -1.13M (-1,180.8%)
|
-250.4K
-250.4K – -250.4K
+77.9% YoY
|
-237.9K
-237.9K – -237.9K
+5.0% YoY
|
| EBIT |
-13.09M
est: -885.3K (-1,378.5%)
|
-13.09M
est: -527.1K (-2,383.4%)
|
-15.00M
est: -1.13M (-1,223.8%)
|
-250.4K
-250.4K – -250.4K
+77.9% YoY
|
-237.9K
-237.9K – -237.9K
+5.0% YoY
|
| Net Income |
-11.94M
est: -19.78M (+39.7%)
|
-11.94M
est: -24.53M (+51.3%)
|
-12.27M
est: -11.07M (-10.9%)
|
-6.77M
-6.77M – -6.77M
+38.8% YoY
|
-14.59M
-14.59M – -14.59M
-115.5% YoY
|
| SGA |
5.02M
est: 4.36M (+15.2%)
|
5.02M
est: 2.59M (+93.6%)
|
4.79M
est: 5.58M (-14.1%)
|
1.23M
1.23M – 1.23M
-77.9% YoY
|
1.17M
1.17M – 1.17M
-5.0% YoY
|
| EPS |
-0.01
est: -0.02 (+28.4%)
|
-0.01
est: -0.03 (+73.1%)
|
-0.01
est: -0.01 (-10.5%)
|
-0.01
-0.01 – -0.01
+38.8% YoY
|
-0.02
-0.02 – -0.02
-115.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Phillip John L'Huillier | Chief Executive Officer & Director | 525.8K | — |
| Lindy Gillian Durrant | Chief Scientific Officer, Director & Founder | 518.9K | — |
| Sathijeevan Nirmalananthan | Chief Financial Officer, Company Secretary & Director | 362.1K | male |
| Mandeep Sehmi | Head of Business Development | — | — |
| Nermeen Varawalla DPHIL | Chief Medical Officer | — | — |
| Philip Angell-Manning | Head of CMC | — | male |
| Samantha Paston | Head of Translational Research | — | — |
| Alex Hayward | Finance Director & Company Secretary | — | male |
| Shamim Kazmi Stokes | Head of Programme Management | — | — |
| Callum Scotthasbeen | Senior Vice President of Development | — | — |
| David Schilansky | Interim Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCNLF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
